{"protocolSection":{"identificationModule":{"nctId":"NCT00382408","orgStudyIdInfo":{"id":"DR-ADV-301"},"organization":{"fullName":"Teva Branded Pharmaceutical Products R&D, Inc.","class":"INDUSTRY"},"briefTitle":"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001"},"statusModule":{"statusVerifiedDate":"2017-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-09"},"primaryCompletionDateStruct":{"date":"2007-12","type":"ACTUAL"},"completionDateStruct":{"date":"2007-12","type":"ACTUAL"},"studyFirstSubmitDate":"2006-09-27","studyFirstSubmitQcDate":"2006-09-27","studyFirstPostDateStruct":{"date":"2006-09-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-07-28","resultsFirstSubmitQcDate":"2012-04-24","resultsFirstPostDateStruct":{"date":"2012-05-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-03-09","lastUpdatePostDateStruct":{"date":"2017-04-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Duramed Research","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.","detailedDescription":"The study will be conducted at two sites and will include a minimum of 4 visits. The overall study duration for participants will be approximately 8 weeks. Study participants will undergo acute respiratory disease evaluation that will include a throat swab and a blood draw. Each participant will also be contacted in six months for follow-up information."},"conditionsModule":{"conditions":["Respiratory Tract Diseases"],"keywords":["Acute respiratory disease prevention","Adenovirus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":4040,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Vaccine","type":"EXPERIMENTAL","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).","interventionNames":["Biological: DR-5001"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"DR-5001","description":"All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.","armGroupLabels":["Vaccine"]},{"type":"OTHER","name":"Placebo","description":"All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.","timeFrame":"Day 0 - Day 56"},{"measure":"Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort","description":"For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the per protocol cohort.","timeFrame":"Day 0 - Day 56"},{"measure":"Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort --- Day 11-56","description":"For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort; further, this outcome omitted ARD cases from Day 0-Day 10 because the protective effect of the vaccine was unlikely to take place during that time period.","timeFrame":"Day 11 - Day 56"},{"measure":"Percentage of Participants Showing ADV-7 Seroconversion at Week 4","description":"ADV-7 seroconversion was defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-7 titer was \\<1:4.","timeFrame":"Week 4"}],"secondaryOutcomes":[{"measure":"Percentage of Participants Showing ADV-4 Seroconversion at Week 4","description":"ADV-4 seroconversion was defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-4 titer was \\<1:4.","timeFrame":"Week 4"},{"measure":"Number of Participants With Wild Type-4 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-4 vaccine, the number of cases of ADV-4 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.","timeFrame":"Day 0 - Day 56"},{"measure":"Percentage of Participants Showing ADV Type-4 Booster at Week 4","description":"ADV-4 booster effect is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-4 titer is ≥1:4.","timeFrame":"Baseline, Week 4"},{"measure":"Number of Participants With Wild Type-7 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-7 vaccine, a secondary outcome is the number of cases of ADV-7 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.","timeFrame":"Day 0 - Day 56"},{"measure":"Number of Participants With Wild Type-7 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-7 vaccine, the number of cases of ADV-7 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.","timeFrame":"Day 0 - Day 56"},{"measure":"Percentage of Participants Showing ADV Type-7 Booster at Week 4","description":"ADV-7 booster effect is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-7 titer is ≥1:4.","timeFrame":"Baseline, Week 4"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Military recruit in training\n* Male or female; if female, must be of non-childbearing potential or with a documented negative pregnancy test \\</= 72 hours prior to study medication administration and agree not to become pregnant\n\nExclusion Criteria:\n\n* Female nursing an infant or planning on nursing during the study\n* Immunosuppressed for any reason, including past (within last 6 months) or current treatment with immunosuppressive therapy\n* Known allergy to any component of the vaccines and/or placebo tablets\n* Immunocompromised sexual partner or immunocompromised individuals in home","healthyVolunteers":true,"sex":"ALL","minimumAge":"17 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Duramed Protocol Chair","affiliation":"Duramed Research, Inc.","role":"STUDY_CHAIR"}],"locations":[{"facility":"Duramed Investigational Site","city":"Great Lakes","state":"Illinois","zip":"60088","country":"United States","geoPoint":{"lat":42.30919,"lon":-87.85007}},{"facility":"Duramed Investigational Site","city":"Fort Jackson","state":"South Carolina","zip":"29207","country":"United States","geoPoint":{"lat":34.04757,"lon":-80.83335}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were randomized to either the vaccine group or the matching placebo group in a 3:1 ratio.","recruitmentDetails":"The study was conducted in subjects undergoing military basic training.","groups":[{"id":"FG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"FG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3031"},{"groupId":"FG001","numSubjects":"1009"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2887"},{"groupId":"FG001","numSubjects":"955"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"54"}]}],"dropWithdraws":[{"type":"Did not meet protocol requirement","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"35"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"BG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3031"},{"groupId":"BG001","value":"1009"},{"groupId":"BG002","value":"4040"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21.3","spread":"4.0"},{"groupId":"BG001","value":"21.1","spread":"4.1"},{"groupId":"BG002","value":"21.2","spread":"4.0"}]}]}]},{"title":"Age, Customized","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19.8","lowerLimit":"17.1","upperLimit":"42.0"},{"groupId":"BG001","value":"19.7","lowerLimit":"17.1","upperLimit":"42.2"},{"groupId":"BG002","value":"19.8","lowerLimit":"17.1","upperLimit":"42.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1121"},{"groupId":"BG001","value":"367"},{"groupId":"BG002","value":"1488"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1910"},{"groupId":"BG001","value":"642"},{"groupId":"BG002","value":"2552"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"African-American","categories":[{"measurements":[{"groupId":"BG000","value":"554"},{"groupId":"BG001","value":"186"},{"groupId":"BG002","value":"740"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"123"}]}]},{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"1871"},{"groupId":"BG001","value":"642"},{"groupId":"BG002","value":"2513"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"326"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"429"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"235"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"3031"},{"groupId":"BG001","value":"1009"},{"groupId":"BG002","value":"4040"}]}]}]},{"title":"Type-4 Titer","description":"Negative = titer value \\<1:4 Positive = titer value \\>=1:4","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Negative","categories":[{"measurements":[{"groupId":"BG000","value":"1906"},{"groupId":"BG001","value":"678"},{"groupId":"BG002","value":"2584"}]}]},{"title":"Positive","categories":[{"measurements":[{"groupId":"BG000","value":"1123"},{"groupId":"BG001","value":"331"},{"groupId":"BG002","value":"1454"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Type-7 Titer","description":"Negative = titer value \\<1:4 Positive = titer value \\>=1:4","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Negative","categories":[{"measurements":[{"groupId":"BG000","value":"1159"},{"groupId":"BG001","value":"377"},{"groupId":"BG002","value":"1536"}]}]},{"title":"Positive","categories":[{"measurements":[{"groupId":"BG000","value":"1870"},{"groupId":"BG001","value":"632"},{"groupId":"BG002","value":"2502"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.","populationDescription":"The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 0 - Day 56","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3031"},{"groupId":"OG001","value":"1009"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"48"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The vaccine efficacy (VE) was defined as: VE = 1 - R, where R = P(vaccine)/P(placebo) was the relative risk of ARD attack in subjects who received vaccines compared to placebos (Blackwelder 1993). The 95% confidence interval of the VE was obtained by inverting the Chi Square method proposed by Koopman for the ratio of two binomial proportions (Koopman 1984). The goal of the analysis of efficacy was to demonstrate a VE of at least 80% with a lower 95% confidence bound at least 60%.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"vaccine efficacy (VE)","paramValue":"99.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"96.02","ciUpperLimit":"99.88"}]},{"type":"PRIMARY","title":"Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort","description":"For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the per protocol cohort.","populationDescription":"The per-protocol (PP) cohort included all participants who met the eligibility criteria set forth in the protocol, did not have any significant violations or deviations from the protocol, and completed the final study visit (Day 56). Subjects who vomited within 24 hours after taking the study medication were excluded from the PP cohort.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 0 - Day 56","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2855"},{"groupId":"OG001","value":"945"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"47"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort --- Day 11-56","description":"For the oral Type-4 vaccine, the primary outcome is the number of cases of ADV-4 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort; further, this outcome omitted ARD cases from Day 0-Day 10 because the protective effect of the vaccine was unlikely to take place during that time period.","populationDescription":"The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 11 - Day 56","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3031"},{"groupId":"OG001","value":"1009"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"44"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Showing ADV-7 Seroconversion at Week 4","description":"ADV-7 seroconversion was defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-7 titer was \\<1:4.","populationDescription":"Type-7 ADV Seroconversion Cohort: Included those subjects who had a negative Type-7 ADV serum neutralizing antibody status at baseline (\\<1:4) and at least one titer value for ADV-7 at the subsequent visits following vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1120"},{"groupId":"OG001","value":"359"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","lowerLimit":"92.4","upperLimit":"95.2"},{"groupId":"OG001","value":"5.3","lowerLimit":"3.0","upperLimit":"7.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Showing ADV-4 Seroconversion at Week 4","description":"ADV-4 seroconversion was defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) after study medication that represented at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline Type-4 titer was \\<1:4.","populationDescription":"Type-4 ADV Seroconversion Cohort: Included those subjects who had a negative Type-4 ADV serum neutralizing antibody status at baseline (\\<1:4) and at least one titer value for ADV-4 at the subsequent visits following vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1841"},{"groupId":"OG001","value":"653"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","lowerLimit":"93.4","upperLimit":"95.5"},{"groupId":"OG001","value":"10.6","lowerLimit":"8.2","upperLimit":"12.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Wild Type-4 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-4 vaccine, the number of cases of ADV-4 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-4 infection. This outcome used the intent-to-treat cohort.","populationDescription":"The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 0 - Day 56","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3031"},{"groupId":"OG001","value":"1009"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"65"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The vaccine efficacy (VE) was defined as: VE = 1 - R, where R = P(vaccine)/P(placebo) was the relative risk of ARD attack in subjects who received vaccines compared to placebos (Blackwelder 1993). The 95% confidence interval of the VE was obtained by inverting the Chi Square method proposed by Koopman for the ratio of two binomial proportions (Koopman 1984). The goal of the analysis of efficacy was to demonstrate a VE of at least 80% with a lower 95% confidence bound at least 60%.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"vaccine efficacy (VE)","paramValue":"98.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"95.39","ciUpperLimit":"99.49"}]},{"type":"SECONDARY","title":"Percentage of Participants Showing ADV Type-4 Booster at Week 4","description":"ADV-4 booster effect is defined as the development of ADV Type-4 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-4 titer is ≥1:4.","populationDescription":"Type-4 ADV Booster Cohort included subjects who had a positive Type-4 ADV serum neutralizing antibody status at baseline (≥ 1:4) and at least one titer value for ADV Type-4 at the subsequent visits following study medication administration.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Week 4","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1094"},{"groupId":"OG001","value":"326"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","lowerLimit":"47.3","upperLimit":"53.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"-0.2","upperLimit":"1.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Wild Type-7 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-7 vaccine, a secondary outcome is the number of cases of ADV-7 febrile acute respiratory disease (ARD), defined as a subject with one or more clinical signs and symptoms of ARD and an oral temperature ≥ 100.5°F (38.06°C) and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.","populationDescription":"The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 0 - Day 56","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3031"},{"groupId":"OG001","value":"1009"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Wild Type-7 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","description":"For the oral Type-7 vaccine, the number of cases of ADV-7 acute respiratory disease (ARD) regardless of whether the participant was febrile or not. Therefore includes participants with one or more clinical signs and symptoms of ARD and throat culture positive for wild ADV Type-7 infection. This outcome used the intent-to-treat cohort.","populationDescription":"The intent-to-treat (ITT) cohort included all participants randomized and treated in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 0 - Day 56","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3031"},{"groupId":"OG001","value":"1009"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Showing ADV Type-7 Booster at Week 4","description":"ADV-7 booster effect is defined as the development of ADV Type-7 neutralizing antibody at Week 4 (Day 26) that represented at least a fourfold increase in titer from baseline (Visit 0) in a participant whose baseline Type-7 titer is ≥1:4.","populationDescription":"Type-7 ADV Booster Cohort included subjects who had a positive Type-7 ADV serum neutralizing antibody status at baseline (≥ 1:4) and at least one titer value for ADV Type-7 at the subsequent visits following study medication administration.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Week 4","groups":[{"id":"OG000","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."},{"id":"OG001","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1815"},{"groupId":"OG001","value":"620"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","lowerLimit":"43.8","upperLimit":"48.4"},{"groupId":"OG001","value":"3.9","lowerLimit":"2.4","upperLimit":"5.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Day 0 (vaccination day) - Day 56","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).","seriousNumAffected":12,"seriousNumAtRisk":1009,"otherNumAffected":916,"otherNumAtRisk":1009},{"id":"EG001","title":"Vaccine","description":"Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).","seriousNumAffected":35,"seriousNumAtRisk":3031,"otherNumAffected":2673,"otherNumAtRisk":3031}],"seriousEvents":[{"term":"BASEDOW'S DISEASE","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"ABDOMINAL PAIN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"ABDOMINAL PAIN UPPER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"GASTRITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"HAEMATOCHEZIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"INGUINAL HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3031}]},{"term":"HERNIA","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"FOOD ALLERGY","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"APPENDICITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"BRONCHITIS ACUTE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"CELLULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3031}]},{"term":"GASTROENTERITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3031}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"PYELONEPHRITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"RESPIRATORY TRACT INFECTION VIRAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"ANKLE FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"CONCUSSION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"FOREARM FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"HIP FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"INTENTIONAL OVERDOSE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":3031}]},{"term":"JAW FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"LIGAMENT INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3031}]},{"term":"LOWER LIMB FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"ROAD TRAFFIC ACCIDENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"SKIN LACERATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"SPINAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"STRUCK BY LIGHTNING","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"ADJUSTMENT DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":3031}]},{"term":"ADJUSTMENT DISORDER WITH ANXIETY","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"ADJUSTMENT DISORDER WITH DEPRESSED MOOD","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"ADJUSTMENT DISORDER WITH MIXED ANXIETY AND DEPRESSED MOOD","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"BIPOLAR DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"CYCLOTHYMIC DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"DEPRESSED MOOD","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"MAJOR DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"PERSONALITY DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"PSYCHOTIC DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"STRESS","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3031}]},{"term":"SUICIDAL IDEATION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"SUICIDE ATTEMPT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"HAEMATURIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]},{"term":"PELVIC PAIN","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1009},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3031}]}],"otherEvents":[{"term":"ABDOMINAL PAIN UPPER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":216,"numAffected":175,"numAtRisk":1009},{"groupId":"EG001","numEvents":593,"numAffected":482,"numAtRisk":3031}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":142,"numAffected":112,"numAtRisk":1009},{"groupId":"EG001","numEvents":484,"numAffected":387,"numAtRisk":3031}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":246,"numAffected":193,"numAtRisk":1009},{"groupId":"EG001","numEvents":654,"numAffected":552,"numAtRisk":3031}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":68,"numAtRisk":1009},{"groupId":"EG001","numEvents":209,"numAffected":181,"numAtRisk":3031}]},{"term":"CHILLS","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":55,"numAtRisk":1009},{"groupId":"EG001","numEvents":86,"numAffected":84,"numAtRisk":3031}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":60,"numAtRisk":1009},{"groupId":"EG001","numEvents":146,"numAffected":139,"numAtRisk":3031}]},{"term":"UPPER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":490,"numAffected":424,"numAtRisk":1009},{"groupId":"EG001","numEvents":1361,"numAffected":1193,"numAtRisk":3031}]},{"term":"PROCEDURAL PAIN","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":134,"numAffected":131,"numAtRisk":1009},{"groupId":"EG001","numEvents":493,"numAffected":475,"numAtRisk":3031}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":372,"numAffected":270,"numAtRisk":1009},{"groupId":"EG001","numEvents":1070,"numAffected":787,"numAtRisk":3031}]},{"term":"BACK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":55,"numAtRisk":1009},{"groupId":"EG001","numEvents":113,"numAffected":110,"numAtRisk":3031}]},{"term":"PAIN IN EXTREMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":79,"numAffected":72,"numAtRisk":1009},{"groupId":"EG001","numEvents":254,"numAffected":233,"numAtRisk":3031}]},{"term":"HEADACHE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":659,"numAffected":447,"numAtRisk":1009},{"groupId":"EG001","numEvents":1795,"numAffected":1237,"numAtRisk":3031}]},{"term":"COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":294,"numAffected":238,"numAtRisk":1009},{"groupId":"EG001","numEvents":855,"numAffected":685,"numAtRisk":3031}]},{"term":"NASAL CONGESTION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":273,"numAffected":226,"numAtRisk":1009},{"groupId":"EG001","numEvents":927,"numAffected":740,"numAtRisk":3031}]},{"term":"PHARYNGOLARYNGEAL PAIN","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":271,"numAffected":233,"numAtRisk":1009},{"groupId":"EG001","numEvents":912,"numAffected":743,"numAtRisk":3031}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"In the past 6 years, Type-7 ADV has only rarely been recovered from recruits with ARD (Russell 2007). Therefore, it may not be possible to directly measure the protective effect of the vaccine against Type-7 ADV in the proposed study."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study."},"pointOfContact":{"title":"Director, Clinical Research","organization":"Teva Branded Pharmaceutical Products, R&D Inc.","email":"info.era-clinical@teva.de","phone":"215-591-3000"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D000257","term":"Adenoviridae Infections"}],"ancestors":[{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}